1. TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer
   Jun Lu et al, 2021, Frontiers in Immunology CrossRef
2. Distinct Benefit of Overall Survival between Patients with Non-Small-Cell Lung Cancer Harboring EGFR Exon 19 Deletion and Exon 21 L858R Substitution
   Nobuyuki Koyama et al, 2017, Chemotherapy CrossRef